Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Impact · against what's priced in

BMY's mixed pipeline results and delayed replacement for Eliquis create near-term headwinds, while MRK faces confirmation of Keytruda's vulnerabilities. The news is largely a wash for the broader group as the market has already factored in the structural patent cliffs and debt burdens facing these peers.

MRK−0.10: Already priced in
The price assumes: A steady continuation of Keytruda's current revenue

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

What matters in this story

Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

What matters in this story

Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?

How each ticker is affected

Connected tickers

Track these names every morning.

Why is Moderna down 10% on Friday?

Onto Innovation: Strong Orders Support Attractive Growth And Valuation

Crown Castle to Report Q3 Earnings: What's in Store for the Stock?

Will Rising Expenses Affect American Express' Q3 Earnings?

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

What matters in this story

Next reads from the same story arc

Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

What matters in this story

Next reads from the same story arc

Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?

How each ticker is affected

Connected tickers

Track these names every morning.

Why is Moderna down 10% on Friday?

Onto Innovation: Strong Orders Support Attractive Growth And Valuation

Crown Castle to Report Q3 Earnings: What's in Store for the Stock?

Will Rising Expenses Affect American Express' Q3 Earnings?